Biocryst Pharmaceuticals has acquired Astria Therapeutics, and with it navenibart, an investigational treatment to prevent swelling attacks in people with hereditary angioedema (HAE). Navenibart is being tested in the Phase 3 ALPHA-ORBIT trial (NCT06842823), which is recruiting patients, ages 12 and older with HAE type…